{"symbol":"BMY","fiscalQuarter":"Q3-2025","reportDate":"2025-10-30","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q3-2025","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Up 7.09%","keyNumbers":[{"metric":"EPS","actual":"$1.63","expected":"N/A","surprise":"+10.14%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on delivering value through our pipeline."],"summary":"Management expressed satisfaction with the earnings beat, highlighting their commitment to innovation and shareholder value. They emphasized the importance of their ongoing projects."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's strong EPS performance, exceeding expectations, has led to a positive stock reaction, with shares rising by 7.09%. This reflects investor confidence in the company's financial health and ongoing projects. However, the lack of revenue data and guidance may leave some investors cautious about future performance.","metaDescription":"Bristol Myers Squibb (BMY) Q3 2025 earnings: EPS beat by 10.14%. Stock up 7.09%. Full breakdown."}}